The first-line treatment for cough related to an upper respiratory tract infection (URI) in a 4-year-old child is:

Rationale: A. Over-the-counter cough and cold preparations containing dextromethorphan and guaifenesin are not recommended for children under 6 years of age. Clinical trials have failed to demonstrate significant efficacy in this age group, and these medications carry a risk of serious adverse effects. The potential for toxicity and accidental overdose outweighs the limited benefits for treating a self-limiting viral cough. B. For pediatric patients with a URI, the focus is on supportive care, including adequate hydration and environmental humification. Fluids help to thin respiratory secretions, making them easier to clear without the need for pharmacological expectorants. This approach avoids the side effects of medications while allowing the child's immune system to resolve the viral infection through natural physiological processes. C. Codeine-containing syrups are strictly contraindicated in the pediatric population due to the risk of life-threatening respiratory depression. The FDA has issued "black box" warnings against the use of codeine for cough in children, especially those under 12 years old. Using an opioid antitussive for a common cold in a 4-year-old represents a significant safety hazard and a deviation from standard pediatric practice. D. Multi-symptom products containing antihistamines and antitussives often cause excessive sedation and other anticholinergic side effects in young children. These agents do not treat the underlying viral cause of the URI and can mask symptoms of worsening illness. First-line pediatric management prioritizes non-pharmacological interventions like honey (for children over 1 year) and saline nasal drops over complex chemical combinations.